基本信息:
- 专利标题： β- amyloid analog -T cell epitope vaccine
- 申请号：JP2009141187 申请日：2009-06-12
- 公开(公告)号：JP5114455B2 公开(公告)日：2013-01-09
- 发明人： ラスムッセン，ペター，ビーク , ジェンセン，マーティン，ローランド , ニールセン，クラウス，グレゴリウス , コエフォエド，ペター , デガン，フローレンス，ダル
- 申请人： エイチ.リュンドベック エイ/エスH.Lundbeck A/S
- 专利权人： エイチ.リュンドベック エイ/エスH.Lundbeck A/S
- 当前专利权人： エイチ．リュンドベック エイ／エスＨ．Ｌｕｎｄｂｅｃｋ Ａ／Ｓ
- 优先权： DKPA200101231 2001-08-20; US33754301 2001-10-22; DKPA200200558 2002-04-16; US37302702 2002-04-16
- 主分类号： A61K39/00
- IPC分类号： A61K39/00 ; C12N15/09 ; A61K20060101 ; A61K35/74 ; A61K35/76 ; A61K38/00 ; A61K39/02 ; A61K39/10 ; A61K39/12 ; A61K39/385 ; A61K39/39 ; A61K39/395 ; A61K45/06 ; A61K48/00 ; A61P20060101 ; A61P3/10 ; A61P25/00 ; A61P25/14 ; A61P25/16 ; A61P25/28 ; C07K20060101 ; C07K14/47 ; C07K19/00 ; C12N1/15 ; C12N1/19 ; C12N1/21 ; C12N5/10
摘要：
Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protien (APP) or beta amyloid (A²). Immunization is preferably effected by administration of analogues of autologous APP or A², said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A² which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against APP or A² and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations
公开/授权文献:
- JP2009280582A β-AMYLOID ANALOG T-CELL EPITOPE VACCINE 公开/授权日：2009-12-03
信息查询:
EspacenetIPC结构图谱:
| A | 人类生活必需 |
| --A61 | 医学或兽医学；卫生学 |
| ----A61K | 医用、牙科用或梳妆用的配制品 |
| ------A61K39/00 | 含有抗原或抗体的医药配制品 |